What is Cullinan Therapeutics, Inc.'s stock issuance proceeds?

Cullinan Therapeutics, Inc. (CGEM) reported stock issuance proceeds of $0 in Q4 2025.

How has Cullinan Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?

Cullinan Therapeutics, Inc.'s stock issuance proceeds decreased by 100.0% year-over-year, from $65.66M to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Cullinan Therapeutics, Inc. CGEM Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron PharmaceuticalsREGN

$163.1M+169%

Janux TherapeuticsJANX

$3.55M+293%

Nektar TherapeuticsNKTR

$1.07B+506,582%

ImmunityBio, Inc.IBRX

$971K+341%

Corvus PharmaceuticalsCRVS

$189.41M+67,788%

Avalo TherapeuticsAVTX

$2.18M—

Other financials

Income statement

See full

Revenue-—

Operating income-$53.7M+2.4%

Net income-$49.7M-2.4%

EPS (diluted)-$0.69+24.2%

Balance sheet

See full

Cash & equivalents$75.1M-2.1%

Total debt$2.4M+29.5%

Total equity$408.7M-30.8%

Total assets$403.0M-30.5%

Cash flow

See full

Operating cash flow-$46.0M-6.7%

CapEx$11.0K—

Free cash flow-$38.1M-4.1%

Valuation

See full

Market cap$1.08B+140%

Enterprise value$1.01B+168%

Profitability

See full

Operating margin-358.7%—

Net margin-346.1%—

Returns & leverage

See full

Return on equity-44%+26.2pp

Debt / equity0×0.0×

Current ratio10.3×-1.3×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Cullinan Therapeutics, Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cullinan Therapeutics, Inc.'s stock issuance proceeds?: Cullinan Therapeutics, Inc. (CGEM) reported stock issuance proceeds of $0 in Q4 2025.
How has Cullinan Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?: Cullinan Therapeutics, Inc.'s stock issuance proceeds decreased by 100.0% year-over-year, from $65.66M to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.